Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Proshares Trust (ZBIO) Profit After Tax (2023 - 2025)

Historic Profit After Tax for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to -$51.5 million.

  • Zenas BioPharma's Profit After Tax fell 3339.9% to -$51.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$189.9 million, marking a year-over-year decrease of 4723.51%. This contributed to the annual value of -$157.0 million for FY2024, which is 32290.7% down from last year.
  • According to the latest figures from Q3 2025, Zenas BioPharma's Profit After Tax is -$51.5 million, which was down 3339.9% from -$52.2 million recorded in Q2 2025.
  • Zenas BioPharma's Profit After Tax's 5-year high stood at $35.6 million during Q3 2023, with a 5-year trough of -$52.6 million in Q4 2024.
  • Its 3-year average for Profit After Tax is -$31.5 million, with a median of -$38.0 million in 2024.
  • In the last 5 years, Zenas BioPharma's Profit After Tax plummeted by 20841.95% in 2024 and then tumbled by 2086.33% in 2025.
  • Zenas BioPharma's Profit After Tax (Quarter) stood at -$24.6 million in 2023, then plummeted by 113.93% to -$52.6 million in 2024, then rose by 2.09% to -$51.5 million in 2025.
  • Its last three reported values are -$51.5 million in Q3 2025, -$52.2 million for Q2 2025, and -$33.6 million during Q1 2025.